Royal Bank of Canada
AARD

Royal Bank of Canada’s Aardvark Therapeutics AARD Stock Holding History

Royal Bank of Canada’s Portfolio AARD Stock Details AARD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1K Sell
180
-419
-70% -$4.34K ﹤0.01% 7002
2025
Q4 		$9K Buy
599
+294
+96% +$3.67K ﹤0.01% 6500
2025
Q3 		$4K Buy
305
+37
+14% +$417 ﹤0.01% 6782
2025
Q2 		$3K Buy
+268
New +$2.76K ﹤0.01% 6767

Other funds holding AARD

DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
TAM
TFG Asset Management Grand Cayman, Cayman Islands $515M AUM 24.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Royal Bank of Canada's AARD Position: Q1 2026 in Review

Royal Bank of Canada reduced its Aardvark Therapeutics (AARD) stake by 70% in Q1 2026, selling an estimated $4.34K and leaving 180 shares worth $1K. The position accounts for ﹤0.01% of the portfolio, ranked #7002.

Royal Bank of Canada first reported a position in AARD in Q2 2025 and has held it in 4 quarters since. The position peaked at $9K in Q4 2025. 79 funds tracked by Wall St. Rank hold AARD as of Q1 2026.

  • Royal Bank of Canada held 180 shares of Aardvark Therapeutics worth $1K as of Q1 2026.
  • Royal Bank of Canada sold 419 Aardvark Therapeutics shares in Q1 2026, an estimated $4.34K.
  • Aardvark Therapeutics made up ﹤0.01% of Royal Bank of Canada's portfolio in Q1 2026, its #7002 holding.
  • Royal Bank of Canada first reported a position in Aardvark Therapeutics in Q2 2025 and has held it in 4 quarters since.
  • Royal Bank of Canada's Aardvark Therapeutics position peaked at $9K in Q4 2025.
  • 79 funds tracked by Wall St. Rank held Aardvark Therapeutics as of Q1 2026.

Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.